JUN 27, 2018 07:06 AM PDT

Cannabis-Based Therapy Drug For The Treatment of Epilepsy

WRITTEN BY: Nouran Amin

A drug derived from marijuana has been the first to be approved by the U.S. Food and Drug Administration for the treatment epilepsy.

The drug, which will be marketed under the name Epidiolex, will specifically seek to treat two serious forms of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. These syndromes are known to begin in childhood and persist in adulthood.

Epidiolex is made from purified cannabidiol (CBD), a compound present in the cannabis plant. CBD is known to have medicinal effects, however, it does not exert the mind-altering high that results from THC, the primary psychoactive component of marijuana.

"This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies," explains FDA Commissioner Scott Gottlieb.

A few states have approved CBD oil in the treatment of intractable epilepsy or seizure disorders.

A drug made from a derivative of marijuana has been approved for patients with certain forms of epilepsy. Blaine Harrington III/Getty Images

"Our biggest concerns with the artisanal [or supplement] versions of CBD were related to the consistency," Carson says. "We can't guarantee the consistency."

Carson believes he will likely prescribe Epidiolex in the future. "I'm always excited about the potential for a new therapy that has been well-studied and has a great potential for benefit," says Carson.

Multiple investigators are examining the efficacy of CBD in the treatment of psychiatric conditions. For example, a clinical study is now underway to examine whether CBD can effectively treat post-traumatic stress disorder and alcohol use disorder. Additionally, another clinical study will test whether CBD could be a potential treatment to help prevent relapse in opioid abusers.

Such approval of Epidiolex will help open the doors to more studies on CBD, which will lift a regulatory hurdle. As of now, the Drug Enforcement Administration placed CBD in the heroin and LSD category as a Schedule 1 substance which mean that these drugs have no medical use potential and only a high abuse substance.

According to Dr. Douglas Throckmorton, deputy director of regulatory programs at the FDA's Center for Drug Evaluation and Research , when CBD is approved as a medical use drug- the DEA will change its classification.

"The DEA will need to make a different scheduling decision for CBD...because it now has an accepted medical use," explains Throckmorton.

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 23, 2019
Drug Discovery & Development
OCT 23, 2019
Medications Used for Atrial fibrillation May Increase Falls
Falls among older adults are a growing health concern that often lead to injury, hospitalization, and other severe complications. Older adults are even at...
OCT 23, 2019
Drug Discovery & Development
OCT 23, 2019
Novel Therapy Shows Promise for Acute Migraines
In a study published in The New England Journal of Medicine, a novel drug, by the name of rimegepant, was found to eliminate pain and reduce characteristic...
OCT 23, 2019
Drug Discovery & Development
OCT 23, 2019
Leukemia Drug Effective for Treating Childhood Brain Cancer
Scientists at the University of California-San Diego have found that a chronic myeloid leukemia drug was found to treat medulloblastoma in mouse models mor...
OCT 23, 2019
Infographics
OCT 23, 2019
Surface Plasmon Resonance (SPR) Technology
Surface plasmon resonance (SPR) allows researchers to investigate different types of biomolecular interactions and mechanisms in real-time and label-free....
OCT 23, 2019
Health & Medicine
OCT 23, 2019
All you need to know about Orphan Drugs
Orphan drugs are medicinal products intended for the diagnosis, prevention, or treatment of very rare life-threatening diseases. To offset the high development cost of orphan drugs, in 1983,...
OCT 23, 2019
Drug Discovery & Development
OCT 23, 2019
Common Drug May Prevent Thousands Deaths from Head Injury
Each year, there are over 60 million new cases of traumatic brain injury (TBI). Mostly caused by road traffic crashes and falls, TBI often causes intracran...
Loading Comments...